Are there any risks?
Most treatments have side effects, which some people may experience, and others may not. EASi-KIDNEYTM is testing vicadrostat (BI 690517) in combination with empagliflozin and both medications have different potential side effects. Importantly, we think the two tablets taken together may reduce the chances of raised potassium levels with vicadrostat (BI 690517, more details below).